PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
==== Australia ==== Salvinorin A is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Escherichia coli: 0.015 μg/mL — 4 μg/mL Klebsiella pneumoniae: 0.06 μg/mL — 16 μg/mL Staphylococcus aureus (methicillin-resistant): 0.03 μg/mL — 2 μg/mL Tigecycline generally has poor activity against most strains of Pseudomonas.
== External links == 5-lipoxygenase-activating+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ALOX5AP genome location and ALOX5AP gene details page in the UCSC Genome Browser.
Sources: en.wikipedia.org
Jackson, A. Y. (1943). Banting as an Artist. Ryerson Press. Shaw, Margaret Mason (1976). Frederick Banting. Fitzhenry & Whiteside. ISBN 978-0-88902-229-4. Stevenson, Lloyd (1946). Sir Frederick Banting. Ryerson Press. Harris, Seale (1946). Banting's miracle; the story of the discoverer of insulin. Lippincott. Walters, Eric (2005). Elixir. Puffin Canada. ISBN 978-0-14-301641-0. Raju, T. N. (1998). "The Nobel Chronicles. 1923: Frederick G Banting (1891–1941), John J R Macleod (1876–1935)". Lancet. 352 (9138): 1482. doi:10.1016/s0140-6736(05)61319-0. PMID 9808029. S2CID 54323266. Hudson, R. P. (1979). "New light on the insulin controversy (Frederick G. Banting and J. J. R. Macleod)". Annals of Internal Medicine. 91 (2): 311. doi:10.7326/0003-4819-91-2-311. PMID 380438. Fletcher, K. (2007). "Sir Frederick Banting homestead sold to developer, family outraged". Canadian Medical Association Journal. 176 (12): 1691–92. doi:10.1503/cmaj.070613. PMC 1877854. PMID 17548378. Shampo, M. A.; Kyle, R. A. (2005). "Frederick Banting – Nobel Laureate for Discovery of Insulin". Mayo Clinic Proceedings. 80 (5): 576. doi:10.4065/80.5.576. PMID 15887423. MacLeod, J. B. A. (2006). "Frederick G. Banting: Giving Prospects for Life from the Past to the New Millennium". Archives of Surgery. 141 (7): 705–07. doi:10.1001/archsurg.141.7.705. PMID 16847245. Elliot, J. C. (2004). "Banting – a Nobel artist". The Medical Journal of Australia. 181 (11–12): 631. doi:10.5694/j.1326-5377.2004.tb06494.x. PMID 15588191. S2CID 10131078. Todhunter, E. N. (1953). "Frederick G.
Copper alloy surfaces have intrinsic properties to destroy a wide range of microorganisms. The US Environmental Protection Agency (EPA), which oversees the regulation of antimicrobial agents and materials in that country, found that copper alloys kill more than 99.9% of disease-causing bacteria within just two hours when cleaned regularly. Copper and copper alloys are unique classes of solid materials as no other solid touch surfaces have permission in the U.S. to make human health claims (EPA public health registrations were previously restricted only to liquid and gaseous products). The EPA has granted antimicrobial registration status to 355 different copper alloy compositions. In healthcare applications, EPA-approved antimicrobial copper products include bedrails, handrails, over-bed tables, sinks, faucets, door knobs, toilet hardware, intravenous poles, computer keyboards, etc. In public facility applications, EPA-approved antimicrobial copper products include health club equipment, elevator equipment, shopping cart handles, etc. In residential building applications, EPA-approved antimicrobial copper products include kitchen surfaces, bedrails, footboards, door push plates, towel bars, toilet hardware, wall tiles, etc. In mass transit facilities, EPA-approved antimicrobial copper products include handrails, stair rails grab bars, chairs, benches, etc.
Ice crossings can be made to support higher loads if they are reinforced, and there are a number of ways this has been done in the past. Also, because these structures are vulnerable to a warming climate, which reduces their operational lifespan, they may benefit from reinforcement along problematic segments, such as creek crossings and where the winter road crosses a shoreline.
== Diseases == Gonadotropin deficiency due to pituitary disease results in hypogonadism, which can lead to infertility. Treatment includes administered gonadotropins, which, therefore, work as fertility medication. Such can either be produced by extraction and purification from urine or be produced by recombinant DNA. Failure or loss of the gonads usually results in elevated levels of LH and FSH in the blood. LH insensitivity, which results in Leydig cell hypoplasia in males, and FSH insensitivity, are conditions of insensitivity to LH and FSH, respectively, caused by loss-of-function mutations in their respective signaling receptors. Another closely related condition to these is GnRH insensitivity.
Sources: en.wikipedia.org
== References == Berk, A A. LISP: the Language of Artificial Intelligence. New York: Van Nostrand Reinhold Company, 1985. 1-25. Lederberg, Joshua. An Instrumentation Crisis in Biology. Stanford University Medical School. Palo Alto, 1963. Lederberg, Joshua. Dendral-64 - a system for computer construction, enumeration and notation of organic molecules as tree structures and cyclic graphs. part i- notational algorithm for tree structures. Interim Report to the National Aeronautics and Space Administration, 15 December, 1964. Lederberg, Joshua. How Dendral Was Conceived and Born. ACM Symposium on the History of Medical Informatics, 5 November 1987, Rockefeller University. New York: National Library of Medicine, 1987. Alternate link to article Lindsay, Robert K., Bruce G. Buchanan, Edward A. Feigenbaum, and Joshua Lederberg. Applications of Artificial Intelligence for Organic Chemistry: The Dendral Project[link removed]. McGraw-Hill Book Company, 1980. Lindsay, Robert K., Bruce G. Buchanan, E. A. Feigenbaum, and Joshua Lederberg. DENDRAL: A Case Study of the First Expert System for Scientific Hypothesis Formation. Artificial Intelligence 61, 2 (1993): 209-261. November, Joseph A. “Digitizing Life: The Introduction of Computers to Biology and Medicine.” Doctoral dissertation, Princeton University, 2006 "Mit smarter Software zur Analytik 4.0." CHEManager (GIT Verlag). Accessed 15 October 2025. "Limitationen von Datenbanken und Möglichkeiten für künstliche Intelligenz." Wiley Analytical Science. Accessed 15 October 2025.
Less than truckload (LTL) cargo is the first category of freight shipment, representing the majority of freight shipments and the majority of business-to-business (B2B) shipments. LTL shipments are also often referred to as motor freight and the carriers involved are referred to as motor carriers. LTL shipments range from 50 to 7,000 kg (110 to 15,430 lb), being less than 2.5 to 8.5 m (8 ft 2.4 in to 27 ft 10.6 in) the majority of times. The average single piece of LTL freight is 600 kg (1,323 lb) and the size of a standard pallet. Long freight and/or large freight are subject to extreme length and cubic capacity surcharges. Trailers used in LTL can range from 28 to 53 ft (8.53 to 16.15 m). The standard for city deliveries is usually 48 ft (14.63 m). In tight and residential environments the 28 ft (8.53 m) trailer is used the most. The shipments are usually palletized, stretch [shrink]-wrapped and packaged for a mixed-freight environment. Unlike express or parcel, LTL shippers must provide their own packaging, as carriers do not provide any packaging supplies or assistance. However, circumstances may require crating or another substantial packaging.
September 20, 2010: United States The National Bureau of Economic Research state that the US left the recession in June 2009, with managing director Lakshman Achuthan of the Economic Cycle Research Institute saying GDP recovered to 70% of the pre-recession level.
X.906|ISO/IEC 19793: Information technology - Open distributed processing - Use of UML for ODP system specifications". This document (usually referred to as UML4ODP) defines use of the Unified Modeling Language 2 (UML 2; ISO/IEC 19505), for expressing the specifications of open distributed systems in terms of the viewpoint specifications defined by the RM-ODP. It defines a set of UML Profiles, one for each viewpoint language and one to express the correspondences between viewpoints, and an approach for structuring them according to the RM-ODP principles. The purpose of "UML4ODP" to allow ODP modelers to use the UML notation for expressing their ODP specifications in a standard graphical way; to allow UML modelers to use the RM-ODP concepts and mechanisms to structure their large UML system specifications according to a mature and standard proposal; and to allow UML tools to be used to process viewpoint specifications, thus facilitating the software design process and the enterprise architecture specification of large software systems. In addition, ITU-T Rec. X.906 | ISO/IEC 19793 enables the seamless integration of the RM-ODP enterprise architecture framework with the Model-Driven Architecture (MDA) initiative from the OMG, and with the service-oriented architecture (SOA).
The peak intensity, or the peak area, from individual molecules (typically proteins) is here correlated to the amount of protein in the sample. However, the individual signal depends on the primary structure of the protein, on the complexity of the sample, and on the settings of the instrument. Other types of "label-free" quantitative mass spectrometry, uses the spectral counts (or peptide counts) of digested proteins as a means for determining relative protein amounts.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.